IBD patients have been found to have a higher risk of lymphoma.

Published Date: 26 Apr 2023

According to researchers from the Karolinska Institutet, patients with Crohn's disease and IBD have an elevated risk of developing lymphoma, and this risk has grown over the past few years.

Read Full News

Latest News

Early Predictors of Crohn’s Disease Recurrence Identified

Guidelines recommend endoscopy at 6-12 months post-resection, but new evidence suggests ultrasound and fecal testing at 3 months can predict higher risk earlier.

How Gut Bugs Use the Vagus Nerve as a Backdoor to the Brain

New research suggests a high-fat diet can turn the vagus nerve into a microbial highway, allowing gut bacteria to breach the brain.

Extent of Family History Not Tied to Pancreatic Cancer Risk

The number of family relatives, first-degree or not, who have pancreatic cancer does not appear to affect the risk for intermediate lesions.

Two Studies Contrast Therapies for Liver Disease

One study compared cost-effectiveness between treatments, the other mortality rates and other long-term outcomes for GLP1-s versus SGLT2 inhibitors.

Mirum's Rare Liver Disease Drug Meets Main Goal in Mid-stage Study

Mirum Pharmaceuticals said on Monday its experimental drug, volixibat, met the main ⁠goal of a mid-stage study by reducing severe itching or pruritus in patients with ⁠a...

Trump Administration Appeals Judge's Order Upending Kennedy's Vaccine Policies

The Trump administration on Wednesday appealed a federal judge's ruling blocking key elements of Health Secretary Robert F. Kennedy Jr.'s push to reshape U.S. vaccine...

Todays Updates

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents

Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk

Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk

Frontline Decisions in Transplant-Ineligible Multiple Myeloma: Evaluating Quadruplet Therapy

Frontline Decisions in Transplant-Ineligible Multiple Myeloma: Evaluating Quadruplet Therapy

GuCS: Genitourinary Cancers Symposium

GuCS Video Pearls: Video Pearls from the Genitourinary Cancers Symposium

GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium

Todays Updates

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents

Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk

Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk

Frontline Decisions in Transplant-Ineligible Multiple Myeloma: Evaluating Quadruplet Therapy

Frontline Decisions in Transplant-Ineligible Multiple Myeloma: Evaluating Quadruplet Therapy

GuCS: Genitourinary Cancers Symposium

GuCS Video Pearls: Video Pearls from the Genitourinary Cancers Symposium

GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium

Latest News

Guidelines recommend endoscopy at 6-12 months post-resection, but new evidence suggests ultrasound and fecal testing at 3 months can predict higher risk earlier.

New research suggests a high-fat diet can turn the vagus nerve into a microbial highway, allowing gut bacteria to breach the brain.

The number of family relatives, first-degree or not, who have pancreatic cancer does not appear to affect the risk for intermediate lesions.

One study compared cost-effectiveness between treatments, the other mortality rates and other long-term outcomes for GLP1-s versus SGLT2 inhibitors.

Mirum Pharmaceuticals said on Monday its experimental drug, volixibat, met the main ⁠goal of a mid-stage study by reducing severe itching or pruritus in patients with ⁠a...

The Trump administration on Wednesday appealed a federal judge's ruling blocking key elements of Health Secretary Robert F. Kennedy Jr.'s push to reshape U.S. vaccine...

News All Time

Preservatives and Cancer: What's the Real Risk?

Patients are increasingly asking about "chemicals" in food. What can clinicians tell them about preservatives and cancer risk?

Drug-Resistant Shigella Surges in Adult Men

Most previous US outbreaks involved children infected with drug-susceptible strains.

Sexual Dysfunction in Digestive Diseases Often Missed

Digestive diseases and treatments may affect sexual function; however, clinicians address these concerns in a minority of patients despite unmet needs.

Celiac Disease Symptoms Vary by Race and Ethnicity

Race- and ethnicity-based disparities in symptom presentation and comorbidity patterns exist among patients with celiac disease.

Locally Advanced Rectal Cancer Responds to HER2 Therapy

Six of eight patients (75%) with HER2-positive rectal adenocarcinoma responded to trastuzumab and tucatinib plus chemotherapy, including four clinical complete responses.

Vitamin C’s Potential Use in Cancer Is Getting a Second Look

Decades after early trials seemed to close the book on vitamin C as a cancer treatment, a member of a group of determined researchers is receiving the therapy himself.

Education Gap Tied to Higher Risk for Young-Onset CRC Death

Researchers analyze trends in colorectal cancer mortality among adults aged 25-49 years in a study spanning about three decades.

Aspirin Unlikely to Cut Colorectal Cancer Incidence

A Cochrane Review finds aspirin likely results in little to no difference in colorectal cancer incidence at a follow-up of 5 years to less than 15 years.

Tumor Genomic Testing: Too Little, Too Late

Tumor genomic testing is critical to informed treatment decisions, but researchers find that it’s used in too few patients and often too late.

High-Impact Exercise Linked to Anal Incontinence in Women

High-impact sports may increase the risk for anal incontinence, especially among women, with many cases underdiagnosed because of stigma and low awareness.

Spyre's Inflammatory Bowel Drug Shown to Reduce Disease Activity in Mid-stage Study

Spyre Therapeutics said on Monday its experimental drug showed a significant reduction in disease activity when ⁠tested in patients with ulcerative colitis in a mid-stage...

Age and Visceral Fat May Trend Together: What to Know

Why fat that surrounds organs is more dangerous continues to be studied.

Vaccination Protects Young Men From HPV-Related Cancers

HPV-related cancers — including anal, penile, and oropharyngeal — are rare in people younger than 50, but new research suggests vaccinated boys could see cancer protection in their teens and 20s.

The Intersection Between Gut and Spine Health

Emerging research is showing more and more connection between the two.

IBD Flare Prediction Improved by Psychosocial Data

Predictive models that combine patient-reported psychosocial measures with clinical data perform well in forecasting flares in patients with inflammatory bowel disease.

Sacral Fracture Risk After Short-Course RT for Rectal Cancer

A recent retrospective analysis assesses the incidence and risk factors for sacral fractures among patients receiving short-course radiation therapy for rectal cancer.

Recommended News For You

Can taking vitamin D supplements every day lower the mortality rate from cancer?

The most precise research tools for the deadliest blood cancer have been developed.

Cancer Patients Are Receiving More and More Stupid Immunotherapy.

Cancer Patients' Depression May Be Helped by Psilocybin.

Childhood cancer survivors face new health problems later in life, study shows

Study finds higher breast cancer rates in areas with more air pollution

Effective Intralesional Melanoma Therapy May Involve Systemic Effects.

Recommended Articles For You

Toripalimab + Nab-Paclitaxel in PD-L1+ TNBC: Phase 3 TORCHLIGHT Trial Results 

Molecular Mechanisms, Clinical Efficacy, and Stem Cell Therapy Integration in Leukemia Treatment 

How Prevident is Revolutionizing Oral Care 

MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Do I have prostate cancer? Why a simple PSA blood test alone won't give you the answer

2.

CDC Alerts on Dramatic Rise in Human Parvovirus B19

3.

Aspirin for CRC Risk Reduction May Benefit Unhealthy People Most

4.

Scientists discover the 'roadmap' that aggressive cancer uses to spread

5.

ASCO: Vepdegestrant ups survival in ER+, HER2− advanced breast cancer with ESR1 mutations

1.

The Next Generation of Precision: How Multi-Specific Antibodies are Redefining Oncology's Future - A 2025 Review

2.

CAR-T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: A Comprehensive Review

3.

The Lowdown on Darbepoetin: Understanding Its Uses and Side Effects 

4.

Exploring Innovative Solutions for Infantile Hemangioma Treatment

5.

Case Study: The Role of Machine Learning in the Detection of Skin Cancer

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC

2.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V

3.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I

4.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V

5.

Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot